Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2023-08-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company 百奥泰生物制药股份有限公司 for the half-year period ending June 30, 2023. It includes specifics on the amount raised, usage of funds, investment projects, regulatory compliance, and cash management of idle funds. The document references regulatory guidelines related to the management and use of raised funds and provides a comprehensive breakdown of the funds' deployment and balance. The document length is 9111 characters, which is substantial and contains detailed financial and operational data related to fundraising activities. This matches the characteristics of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report publication, nor a general regulatory filing, but a substantive report on fundraising usage and management.
2023-08-24 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a financial institution (China International Capital Corporation) acting as the sponsor for a pharmaceutical company's IPO on the STAR Market (科创板). It discusses the use of idle raised funds temporarily supplementing working capital, referencing regulatory guidelines, board and supervisory approvals, independent director opinions, and compliance with listing rules. The document includes detailed financial figures, project investment plans, and multiple board meeting resolutions. It is not a brief announcement but a comprehensive verification and opinion report on the use of funds, which aligns with an audit or verification report rather than a full annual or interim report. The document is not a simple announcement or certification but a substantive audit-related opinion on the use of IPO proceeds and compliance with regulations. Therefore, it fits best under Audit Report / Information (AR).
2023-08-24 Chinese
百奥泰 关于申请开具保函并提供质押担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 百奥泰生物制药股份有限公司 regarding the company's application to issue a bank guarantee and provide pledge collateral. It details the board meeting resolutions, the parties involved, the guarantee amount, and the pledge contract. There is no financial report, earnings data, or management discussion of financial results. The document is a formal announcement of a financing-related transaction (bank guarantee and pledge) rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the transaction. Therefore, the document fits best under Capital/Financing Update (CAP).
2023-08-24 Chinese
百奥泰 2023年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report." It contains detailed financial data for the first half of 2023, including revenue, net profit, cash flow, and other financial indicators. It also includes management discussion and analysis, company business overview, product information, and risk factors. The document is comprehensive and lengthy (15,000 characters), containing actual financial statements and substantive analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence.
2023-08-24 Chinese
百奥泰第二届监事会第九次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 9th meeting of the 2nd Supervisory Board of 百奥泰生物制药股份有限公司. It discusses the approval of the company's 2023 semi-annual report and related financial and regulatory matters. The document references the 2023 semi-annual report and other related reports but does not contain the actual financial statements or detailed financial data itself. It also provides links and references to where the full reports can be found. The document length is 3152 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an announcement of the supervisory board's resolutions regarding the semi-annual report and related matters, not the report itself. According to the classification rules, such announcements are best classified as Regulatory Filings (RNS) because they do not contain the full financial report but are regulatory disclosures about the report and related approvals.
2023-08-24 Chinese
百奥泰生物制药股份有限公司 独立董事关于第二届董事会第十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several proposals discussed at the company's board meeting, including the use of raised funds, temporary use of idle funds, and guarantee business. It references compliance with company law and stock exchange rules, and it is a formal opinion related to board meeting matters rather than a full report or financial statement. The document length is short (1131 characters) and it does not contain financial statements or detailed financial data. It is not an announcement of voting results or a regulatory filing. The content fits best with Board/Management Information (MANG) as it relates to board meeting decisions and management proposals.
2023-08-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.